[1] WANG J, ZHAO Y, WANG Q, et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment[J]. Cancer Biol Med, 2018, 15(4):443-451. [2] 林洽雄. 三种含铂类化疗方案治疗晚期非小细胞肺癌的疗效和药物经济学分析[J]. 北方药学, 2019, 16(5):166-167. [3] BISHNU A, SAKPAL A, GHOSH N, et al. Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells[J]. Int J Biochem Cell Biol, 2019, 107:116-127. [4] ZHANG C, WANG Y C. Metformin attenuates cells stemness and epithelial-mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β-catenin pathway[J]. Mol Med Rep, 2019, 19(2):1203-1209. [5] ZAKIKHANI M, BLOUIN M J, PIURA E, et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells[J]. Breast Cancer Res Treat, 2010, 123(1):271-279. [6] LKHAGVADORJ S, OH S S, LEE M R, et al. Insulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis[J]. Yonsei Med J, 2014, 55(4):861-870. [7] LEVY A, DOYEN J. Metformin for non-small cell lung cancer patients:Opportunities and pitfalls[J]. Crit Rev Oncol Hematol, 2018, 125:41-47. [8] 李丽静,臧亚茹,于文会,等. 化疗联合斑蝥酸钠维生素B6注射液对非小细胞肺癌患者的治疗效果及其机制[J]. 吉林大学学报(医学版), 2018, 44(6):1286-1290. [9] TAS F, BILGIN E, TASTEKIN D, et al. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer[J]. Biomed Rep, 2016, 4(5):609-614. [10] 徐立群,张荣华,邹莹,等. 参慈胶囊联合顺铂通过PI3K/AKT/mTOR信号通路逆转人肺腺癌顺铂耐药的机制研究[J]. 中国病理生理杂志, 2017, 33(3):500-504. [11] SOSNICKI S, KAPRAL M, WEGLARZ L. Molecular targets of metformin antitumor action[J]. Pharmacol Rep, 2016, 68(5):918-925. [12] XU T, LI D, HE Y, et al. Prognostic value of metformin for non-small cell lung cancer patients with diabetes[J]. World J Surg Oncol, 2018, 16(1):60. [13] LUND-IVERSEN M, SCOTT H, STROM E H, et al. Expression of estrogen receptor-alpha and survival in advanced-stage non-small cell lung cancer[J]. Anticancer Res, 2018, 38(4):2261-2269. [14] 方志红,李天苗,许荣忠,等. 246例非小细胞肺癌的预后影响因素分析[J]. 现代肿瘤医学, 2017, 25(8):1234-1236. [15] YANG H L, LI X D, SHI J L, et al. A nomogram to predict prognosis in patients undergoing sublobar resection for stage IA non-small-cell lung cancer[J]. Cancer Manag Res, 2018, 10:6611-6626. [16] 秦舣,黄媚娟,李艳莹,等. 晚期非小细胞肺癌长期生存患者临床特征及治疗相关因素分析[J]. 华西医学, 2019, 34(1):12-17. [17] LIU X J, LIU B Y, CUI Y, et al. Collagen triple helix repeat containing 1(Cthrc1) is an independently prognostic biomarker of non-small cell lung cancers with cigarette smoke[J]. Tumour Biol, 2014, 35(11):11677-11683. [18] XIAO F, LIU D R, GUO Y Q, et al. Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis[J]. J Thorac Dis, 2017, 9(4):990-1001. [19] KOYAMA N, WATANABE Y,IWAI Y, et al. Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion[J]. Neoplasma, 2018, 65(1):132-139. [20] GASPARRI M L, BESHARAT Z M, FAROOQI A A, et al. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells:A potential role in platinum resistance[J]. J Cancer Res Clin Oncol, 2018, 144(12):2313-2318. [21] ZHANG N B, LIU H, CUI M, et al. Direct determination of the binding sites of cisplatin on insulin-like growth factor-1 by top-down mass spectrometry[J]. J Biol Inorg Chem, 2015, 20(1):1-10. [22] 李雪萍,梁鑫,刘政,等.LncRNA LOC90024对肺癌细胞生长、迁移和侵袭的影响[J].西安交通大学学报(医学版),2019,40(1):43-48. |